0001209191-23-004122.txt : 20230119 0001209191-23-004122.hdr.sgml : 20230119 20230119202836 ACCESSION NUMBER: 0001209191-23-004122 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230117 FILED AS OF DATE: 20230119 DATE AS OF CHANGE: 20230119 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bergstrom Donald A CENTRAL INDEX KEY: 0001709772 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39385 FILM NUMBER: 23538718 MAIL ADDRESS: STREET 1: 840 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Relay Therapeutics, Inc. CENTRAL INDEX KEY: 0001812364 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 399 BINNEY STREET STREET 2: 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-370-8837 MAIL ADDRESS: STREET 1: 399 BINNEY STREET STREET 2: 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-01-17 0 0001812364 Relay Therapeutics, Inc. RLAY 0001709772 Bergstrom Donald A C/O RELAY THERAPEUTICS, INC. 399 BINNEY STREET, 2ND FLOOR CAMBRIDGE MA 02139 0 1 0 0 President, R&D Common Stock 2023-01-17 4 A 0 160390 0.00 A 246276 D Stock Option (Right to Buy) 20.45 2023-01-17 4 A 0 160390 0.00 A 2033-01-16 Common Stock 160390 160390 D Stock Option (Right to Buy) 20.45 2023-01-17 4 A 0 160390 0.00 A 2033-01-16 Common Stock 160390 160390 D Represents restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. Includes 232,849 shares underlying RSUs The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments commencing on January 17, 2023, subject to the reporting person's continued service with the Issuer through each vesting date. Such option was granted pursuant to the terms of the Issuer's 2020 Stock Option and Incentive Plan and becomes exercisable, if at all, in twelve equal quarterly installments if the last quoted trading price per share of the Issuer's common stock on the Nasdaq Global Market during any fifteen consecutive calendar day period is at least $35.00; provided that the reporting person maintains a service relationship with the Issuer. /s/ Brian Adams, as Attorney-in-Fact 2023-01-19